311 related articles for article (PubMed ID: 30124494)
1. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
Horita Y; Nishino M; Sugimoto S; Kida A; Mizukami A; Yano M; Arihara F; Matsuda K; Matsuda M; Sakai A
Anticancer Drugs; 2019 Jan; 30(1):98-104. PubMed ID: 30124494
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT
Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
7. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
8. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Pegram MD; Bondarenko I; Zorzetto MMC; Hingmire S; Iwase H; Krivorotko PV; Lee KS; Li RK; Pikiel J; Aggarwal R; Ewesuedo R; Freyman A; Li R; Vana A; Yin D; Zacharchuk C; Tan-Chiu E
Br J Cancer; 2019 Jan; 120(2):172-182. PubMed ID: 30568294
[TBL] [Abstract][Full Text] [Related]
9. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Satoh T; Xu RH; Chung HC; Sun GP; Doi T; Xu JM; Tsuji A; Omuro Y; Li J; Wang JW; Miwa H; Qin SK; Chung IJ; Yeh KH; Feng JF; Mukaiyama A; Kobayashi M; Ohtsu A; Bang YJ
J Clin Oncol; 2014 Jul; 32(19):2039-49. PubMed ID: 24868024
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Ocana A; Gil-Martin M; Antolín S; Atienza M; Montaño Á; Ribelles N; Urruticoechea A; Falcón A; Pernas S; Orlando J; Montero JC; Escudero MJ; Benito S; Caballero R; Carrasco E; Rojo F; Pandiella A; Ruiz-Borrego M
Breast Cancer Res Treat; 2019 Apr; 174(3):693-701. PubMed ID: 30607629
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
14. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
de Langen AJ; Jebbink M; Hashemi SMS; Kuiper JL; de Bruin-Visser J; Monkhorst K; Thunnissen E; Smit EF
Br J Cancer; 2018 Aug; 119(5):558-564. PubMed ID: 30061586
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
Oh SY; Lee S; Huh SJ; Lee J; Kim ST; Park SH; Lim HY; Kang WK; Kang BW; Kim JG; Lee HJ; Kim JH; Kang JH; Kim H
Cancer Chemother Pharmacol; 2019 Mar; 83(3):501-508. PubMed ID: 30535535
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
20. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
